Statin Drug Interactions
Statin interactions primarily involve CYP3A4 and OATP1B1 transporter inhibition, raising statin plasma levels and the risk of myopathy and rhabdomyolysis.
Why Statin Interactions Are Dangerous
Statin myopathy and rhabdomyolysis are concentration-dependent adverse effects. Drug interactions that increase statin plasma levels elevate these risks substantially. The cerivastatin-gemfibrozil combination caused over 50 rhabdomyolysis deaths before cerivastatin was withdrawn in 2001.
Metabolic Pathways
Different statins use different metabolic routes, creating distinct interaction profiles:
| Statin | Primary CYP | OATP1B1 | Interaction Risk |
|---|---|---|---|
| Simvastatin | CYP3A4 | Yes | Highest |
| Lovastatin | CYP3A4 | Yes | High |
| Atorvastatin | CYP3A4 | Yes | Moderate |
| Rosuvastatin | CYP2C9 (minor) | Yes | Lower |
| Pravastatin | Non-CYP | Yes | Lowest |
| Pitavastatin | Minimal CYP | Yes | Low |
CYP3A4-Mediated Interactions
Simvastatin and lovastatin are the most vulnerable. Strong CYP3A4 inhibitors can increase their AUC by 10-20 fold:
- Contraindicated: itraconazole, ketoconazole, posaconazole, HIV protease inhibitors (except with dose-limited atorvastatin), clarithromycin
- Dose limits: simvastatin max 20 mg with amiodarone, amlodipine, or diltiazem; max 10 mg with lomitapide
- Moderate inhibitors: erythromycin, verapamil, fluconazole — require dose reduction
Atorvastatin is less sensitive but not immune. Combining atorvastatin with itraconazole increases its AUC 3-fold.
OATP1B1 Transporter Interactions
OATP1B1 mediates hepatic uptake of all statins. Inhibitors cause systemic statin accumulation:
- Cyclosporine — the most potent OATP1B1 inhibitor; increases rosuvastatin AUC 7-fold, pravastatin 5-fold. Most statins are contraindicated or severely dose-limited with cyclosporine.
- Gemfibrozil — inhibits OATP1B1 and glucuronidation; increases simvastatin acid AUC 2-3 fold. Combination with any statin increases myopathy risk. FDA recommends avoiding gemfibrozil-statin combinations; fenofibrate is preferred.
Other Interactions
- Colchicine — independent myotoxicity; combined with statins increases myopathy risk, especially in renal impairment
- Daptomycin — causes myopathy independently; consider temporarily holding statins during daptomycin courses
- Niacin — modest additive myopathy risk at doses above 1 g/day
- Grapefruit juice — inhibits intestinal CYP3A4; clinically relevant for simvastatin and lovastatin with large quantities (>1 quart/day)
Safe Prescribing
- Prefer low-interaction statins (rosuvastatin, pravastatin, pitavastatin) in patients on complex regimens
- Check FDA-recommended dose limits for each statin-inhibitor pair before prescribing
- Counsel patients to report unexplained muscle pain, tenderness, or dark urine immediately
- Check CK only if symptomatic; routine CK monitoring is not recommended
- Use fenofibrate instead of gemfibrozil when fibrate-statin combination is needed
Key Takeaways
- Simvastatin and lovastatin have the highest interaction risk due to CYP3A4 dependence
- Cyclosporine inhibits OATP1B1, dramatically increasing all statin levels
- Gemfibrozil-statin combinations increase myopathy risk; use fenofibrate instead
- Rosuvastatin, pravastatin, and pitavastatin have the lowest CYP-mediated interaction risk
- FDA dose limits exist for many statin-inhibitor pairs; consult product labeling